Carnegie Mellon University and Mastercard Foundation Partner to Drive Youth-Led Digital Transformation in Africa
8.9.2022 15:00:00 EEST | Business Wire | Press release
Carnegie Mellon University (CMU) and the Mastercard Foundation, in collaboration with the Government of Rwanda, today announced a transformational investment in higher education and innovation in Africa to catalyze opportunities for 10,000 young people from economically disadvantaged communities—particularly young women, young people with disabilities, and forcibly displaced young people—and to drive inclusive development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220908005003/en/
Carnegie Mellon University Africa Kigali, Rwanda (Photo: Business Wire)
The $275.7 million partnership with the Mastercard Foundation will significantly expand advanced engineering and technology education at CMU-Africa in Kigali. The investment from the Foundation includes a $175M endowment to perpetually fund CMU-Africa. It also includes $100.7M to establish CMU-Africa’s Center for the Inclusive Digital Transformation of Africa.
Specifically, through this historic partnership with the Mastercard Foundation, CMU-Africa will:
- Expand instructional capacity, including introducing a new degree in engineering artificial intelligence, and online learning programs.
- Grow the annual cohort of students enrolling in CMU-Africa by more than 33%.
- Provide additional financial assistance to more CMU-Africa students, including increased support for the Mastercard Foundation Scholars Program at CMU-Africa. The partnership will provide direct scholarship support to a total of 300 students.
- Ensure programs recruit and provide opportunities for marginalized groups, including women, people with disabilities, and displaced people.
- Pilot programs for English language immersion to help prepare undergraduate students from other African universities for graduate study.
The new partnership will also strengthen Africa’s research, entrepreneurship, and innovation ecosystem more broadly by:
- Establishing a network of higher education institutions in Africa that will work with the private sector and governments to create the conditions for inclusive digital transformation.
- Supporting up to 10 African universities to deliver high-quality engineering and technology education.
- Increasing digital knowledge creation to drive technology development and job-creating innovation through training, seed funding, and collaboration opportunities for researchers at CMU-Africa and other partner universities.
- Directly involving faculty and staff from CMU-Pittsburgh in CMU-Africa activities to innovate in education and help create the knowledge needed to drive the inclusive digital transformation of Africa in fields that include agriculture, health, and finance, among others.
Through these various pillars of the partnership, a total of 10,000 young people will gain the skills to compete in the global marketplace, innovate, design new tools that solve regional and global challenges, and bring those tools to market.
Carnegie Mellon is the only U.S. research university with master’s degree programs and full-time faculty, staff, and operations on the continent. CMU-Africa was established in 2011 through a partnership between Carnegie Mellon University and the Government of Rwanda. Through the strategic collaboration and generous support of the Government of Rwanda and the Rwandan people, CMU-Africa has built a strong educational platform that serves the continent.
“The key to creating opportunities for promising African students from all socioeconomic backgrounds is access to education in the high-tech fields that are driving the economies of the future,” said Farnam Jahanian, president of Carnegie Mellon University. “We are grateful to the Mastercard Foundation for their partnership with CMU over the past six years to help empower the next generation of Africa’s leaders, and we are delighted to be expanding our partnership even further. With this new collaboration, we will accelerate our shared mission and provide life-changing educational and career experiences for students across the continent.”
Africa has the youngest and fastest-growing population in the world. By 2030, there will be 375 million young people in the job market in Africa, and that number is expected to grow to more than a billion people within the next few decades. Young people in Africa represent the workforce of tomorrow and can serve as a force for Africa’s transformation if they have the skills and knowledge to participate in and build the economies of the future.
“Mastercard Foundation Scholars and graduates from this program will be at the forefront of creating technologies and companies that will generate jobs and enhance Africa's economic competitiveness. We are excited that this initiative will strengthen the role of African universities in developing the continent's scientists, innovators, and problem-solvers as well as generating knowledge that will benefit society more broadly,” said Reeta Roy, president and CEO of the Mastercard Foundation.
The new initiative builds on a previous partnership between the Mastercard Foundation and Carnegie Mellon University, as well as a successful 10-year partnership between the Government of Rwanda and CMU-Africa that has connected 561 young people from 21 African countries to world-class training—including 125 students supported through the Mastercard Foundation Scholars Program.
“The strategic partnership with Carnegie Mellon University is one of the Government of Rwanda’s key investments to support the development of a critical mass of skills in science and technology, particularly in ICT, required by the knowledge economy and to help accelerate Rwanda’s and the region’s socioeconomic transformation. We express our sincere appreciation to the Mastercard Foundation for their significant support, which will help Rwanda realize its vision for the future in establishing the Regional Center of Excellence in Rwanda (CMU-Africa) and ensure the sustainability of the program. The Regional Center of Excellence, coupled with other important strategies will help ensure that we are part of, and benefit from, the global digital revolution,” said Valentine Uwamariya, minister of education in Rwanda.
CMU-Africa offers graduate degrees in information technology, electrical and computer engineering, and engineering artificial intelligence through Carnegie Mellon’s top-ranked College of Engineering, with the same standards, curricula, and requirements as its Pittsburgh campus. As of spring 2022, the program enrolled over 230 students representing 21 African countries.
“The Mastercard Foundation’s support will enable us to accelerate our Africa strategy, which is uniquely defined to prepare higher education students to meet the complex needs of the digital future along with the research and entrepreneurship necessary to compete in the global economy,” said William Sanders, dean of the College of Engineering.
CMU-Africa’s impact includes a close to 90% employment rate within the first year of graduation. Its alumni have founded or joined startup companies, are pursuing their Ph.D.’s in top doctoral programs in the U.S. and Europe, and are serving in government information offices, including within the Government of Rwanda and the World Bank.
“The Mastercard Foundation has been a critical partner in the growth of CMU-Africa as we help meet the growing demand for high-quality technical talent who will accelerate development on the continent,” said Allen Robinson, director of CMU-Africa and associate dean for international programs in Africa. “This new, extraordinary phase of our relationship will exponentially magnify our ability to build a pan-African network that positively impacts the future of young people across the continent.”
About the Mastercard Foundation:
The Mastercard Foundation works with visionary organizations to enable young people in Africa and in Indigenous communities in Canada to access dignified and fulfilling work. It is one of the largest, private foundations in the world with a mission to advance learning and promote financial inclusion to create an inclusive and equitable world. The Foundation was created by Mastercard in 2006 as an independent organization with its own Board of Directors and management. For more information on the Foundation, please visit:
www.mastercardfdn.org
. Follow Mastercard Foundation on Twitter at: @MastercardFdn.
About Carnegie Mellon University:
Carnegie Mellon, cmu.edu, is a private, internationally ranked research university with acclaimed programs spanning the sciences, engineering, technology, business, public policy, humanities, and the arts. Our diverse community of scholars, researchers, creators, and innovators is driven to make real-world impacts that benefit people across the globe. With a bold, interdisciplinary, and entrepreneurial approach, we do the work that matters.
About the College of Engineering and CMU-Africa:
The College of Engineering at Carnegie Mellon University is a top-ranked engineering college that is known for our Advanced Collaboration culture in research and education. The College is well-known for working on problems of both scientific and practical importance. Our “maker” culture is ingrained in all that we do, leading to novel approaches and transformative results. Our acclaimed faculty have a focus on innovation management and engineering to yield transformative results that will drive the intellectual and economic vitality of our community, nation, and world.
CMU-Africa was established in 2011 through a partnership between Carnegie Mellon and the Government of Rwanda. CMU-Africa is the only U.S. research university offering its master’s degrees with a full-time faculty, staff, and operations in Africa. The institution is addressing the critical shortage of high-quality engineering talent required to accelerate the economic transformation of the African continent. For more information on the Engineering program in Africa, please visit: africa.engineering.cmu.edu . Follow us on Twitter at @CMUEngineering and @CMU_Africa.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005003/en/
Contact information
Media Contacts:
Carnegie Mellon University
Pittsburgh, Pennsylvania (US)
Hannah Diorio-Toth
+1 412.268.1208
hdiorio@andrew.cmu.edu
Sherry Stokes
+1 412.268.5976
stokes@cmu.edu
Kigali, Rwanda (Africa)
Monica Sumbi
+250 791.568.962
msumbi@andrew.cmu.edu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
